Ticker

SHANGHAI, Feb. 26, 2026 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that the Company will effectuate a 1-for-8 share consolidation of the Company's ordinary shares of US$0.001 par value each (the "Share Consolidation"). Beginning with the opening of…

Zhongchao Inc. (NASDAQ: ZCMD - Get Free Report) saw a large increase in short interest in the month of February. As of February 13th, there was short interest totaling 155,000 shares, an increase of 610.1% from the January 29th total of 21,827 shares. Based on an average daily volume of 8,954,725 shares, the days-to-cover ratio is

10x Genomics (NASDAQ: TXG - Get Free Report) and Zhongchao (NASDAQ: ZCMD - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership. Analyst Ratings This is a summary of current ratings

Zhongchao Inc. (NASDAQ: ZCMD - Get Free Report) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totaling 162,112 shares, a growth of 667.1% from the December 15th total of 21,132 shares. Approximately 0.9% of the shares of the stock are sold short. Based on

Pulmonx (NASDAQ: LUNG - Get Free Report) and Zhongchao (NASDAQ: ZCMD - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability. Profitability This table compares Pulmonx and Zhongchao's net margins,